Neogen Corp

Neogen trades with a strikingly absent P/E ratio, signaling persistent unprofitability despite its $2.1B market cap—a notable red flag in the diagnostics space where competitors typically demonstrate earnings. The RSI of 45.3 suggests neither overbought nor oversold conditions, leaving the stock in neutral technical territory. With 6.16% short interest and trading well below its 52-week high, the setup indicates tepid enthusiasm rather than panic selling. For a company in the high-margin diagnostic substances industry, the lack of profitability metrics raises questions about execution, competitive positioning, or whether losses are temporary investments in growth infrastructure.